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ABSTRACT
Lymphangioleiomyomatosis (LAM) is a rare lung disease
affecting almost exclusively young women, characterised by
abnormal proliferation of atypical smooth muscle cells. We
describe a young woman presenting with chyluria secondary
to the presence of a large retroperitoneal lymph -
angioleiomyoma. Immunohistochemical analysis revealed
HMB45-negative LAM cells (HMB45 staining is absent only in
rare cases) expressing low levels of estrogen receptors.
Estrogen suppressive treatment with triptoreline, a synthetic
analogue of Gn-RH, resulted in dramatic reduction of the
retroperitoneal mass size. The role of estrogens in the patho-
genesis of LAM remains poorly understood, and hormonal
therapy is still debated, but this case suggests that at least in
some LAM patients, possibly those with HMB45-negative dis-
ease and estrogen receptor expression, hormonal therapy
may be effective in controlling the disease process. 
Keywords: Chyluria, lymphangioleiomyoma, lymphangioleio -
myomatosis, triptoreline.
RIASSUNTO 
La linfangioleiomiomatosi (LAM) è una rara patologia polmo-
nare che colpisce quasi esclusivamente donne giovani, carat-
terizzata da un’anomala proliferazione di cellule muscolari li-
sce atipiche. Descriviamo il caso di una giovane donna presen-
tatasi con chiluria secondaria alla presenza di un vasto linfan-
gioleiomioma retroperitoneale. L’immunoistochimica rivelava
LAM-cells negative per l’HMB45 e bassi livelli di recettori
estrogenici. 
Il trattamento di soppressione estrogenica con triptorelina,
un analogo sintetico del GnRH ha determinato una notevole
riduzione della massa retroperitoneale. Il ruolo degli estroge-
ni nella patogenesi della LAM non è stato ancora completa-
mente chiarito e la terapia ormonale è ancora dibattuta, ma
questo caso suggerisce che, almeno in alcune pazienti con
LAM cells HMB45-negative e con espressione dei recettori per
estrogeni, la terapia ormonale può essere efficace nel control-
lare la patologia.
Parole chiave: Chiluria, linfangioleiomioma, linfangioleiomio-
matosi, triptorelina.
Lymphangioleiomyomatosis (LAM) is a rare, pro-
gressive, frequently fatal lung disease. It affects al-
most exclusively pre-menopausal women and is ex-
acerbated by pregnancy and exogenous estrogens,
thus suggesting a role for estrogens in its etiology
and pathology. LAM is predominantly sporadic, ow-
ing to somatic mutations in tuberous sclerosis
genes, but it may also manifest in the context of
tuberous sclerosis complex (TSC), an autosomal
dominant disorder of highly variable penetrance
[1,2]. The pathologic hallmark of LAM is the abnor-
mal and potentially metastatic growth of atypical
smooth muscle (SM)-like cells (LAM cells) within
the lungs and axial lymphatics. LAM cells typically
express the melanoma-related antigen HMB-45 [3].
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7 In the lung, the typical lesions are thin-walled
parenchymal cysts, which cause destruction of the
interstitium and progressive air-flow obstruction [4].
In addition to the lung cysts, LAM is also character-
ized by renal or abdominal angiomyolipomas,
perivascular tumors consisting of a mixture of LAM
cells, fat cells and blood vessels [5]. A recent report
including both patients with TSC and sporadic LAM
showed that sirolimus monotherapy reduced 
angiomyolipoma volume by nearly 50%.
Conversely, improvements in airflow and gas trap-
ping were limited to patients with LAM [6].
However, the rate of adverse effects was high, and
only a small number of patients had renal and pul-
monary benefits that persisted after the drug was
stopped. Another recent report [7] shows that treat-
ment with sirolimus for 1 year has beneficial effects
in patients with LAM, including the stabilization of
forced expiratory volume in 1 second (FEV1) and
improvement in forced vital capacity (FVC), quality
of life, and some func-tional performance meas-
ures. But sirolimus therapy positively affected lung
function only during the treatment period and it was
associated with a large number of different adverse
events. 
Despite these somewhat promising results, and de-
spite the recently reported effect of hormonal 
manipulation [8], effective treatment for patients
with LAM is still lacking.
CASE REPORT
We describe a 42-year old Italian pre-menopausal
woman, current smoker. She reported the use of
hormonal therapy as a contraceptive measure, dis-
continued 2 years before presenting at our hospi-
tal, with irrelevant familiar and past medical history,
apart from a voluntary abortion at age 25. No history
of tuberous sclerosis was present. In July 2006 she
reported an acute flu-like syndrome with fever and
diffuse abdominal pain, relieved by paracetamol
administration. One month later, chyluria associat-
ed to mild left flank pain appeared, in the absence
of urinary symptoms; echographic examination of
the abdomen revealed a tubular mass with a maxi-
mum diameter of 2 cm, as well as pseudocystic 
lesions around the right ureter with mild left 
hydronephrosis. A computerized tomography (CT)
scan confirmed the presence of a large retroperi-
toneal mass, initially interpreted as conglomerated
lymph nodes, dislocating both ureters, the lower
tract of the vena cava and the abdominal tract of the
aorta (Figure 1, panel A). In the left kidney a 1.4 cm
renal cyst was identified, while the uterus was en-
larged by an endoluminal 2 cm nodule (later diag-
nosed as a myoma by transvaginal echography).
Radiographic examination of the urinary tract by
urography confirmed that the left ureter was com-
pressed and dislocated by the neoformation. During
a cystoscopic examination, white, milk-like urine
from the left ureteral ostium was identified and a
permanent left ureteral stent was inserted. In
October 2006 the patient was admitted to the
Oncology department, where a laparoscopy and
biopsy of the retroperitoneal tissue were performed.
Histologic examination revealed nodular infiltration
by SM cells: immunohistochemical analysis
showed that these muscle cells stained positive with
antibodies specific for desmin (clone D240) and 
α-actin (clone HHF35), while they were negative
for anti-CD34 (clone QBEND10), S100 protein
(polyclonal), melanoma-associated antigen (clones
HMB-45 and MART-1) and cytokeratin (clones
MNF116, 35βH11 and 34βE12) antibodies.
Staining for α and β  estrogen receptors (ERs) was
almost completely negative. A brain MRI was nor-
mal. Chest examination was normal as were arterial
blood gases. Body plethysmography was within nor-
mal values (FEV1 3.2 L, 116% predicted; FVC 3.9 L,
121% predicted; total lung capacity [TLC] 6.3 L,
FIGURE 1: MULTI-SLICE SPIRAL COMPUTED TOMOGRAPHY (CT), CORONAL REFORMATTED IMAGE SHOWING A
RETROPERITONEAL MASS LOCATED IN CLOSE PROXIMITY TO THE THORACIC DUCT BEFORE (PANEL A) AND AFTER (PANEL B)
TREATMENT WITH TRIPTORELINE
A B
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127% predicted; residual volume [RV] 1.7 L, 102%
predicted), whereas carbon monoxide diffusion was
slightly reduced (DLCO 77% predicted). Chest high-
resolution computed tomography (HRCT) showed
thin-walled cysts with an average diameter of 5
mm, diffused to both upper lobes (Figure 2); the tho-
racic duct was moderately enlarged. Trans-
bronchial biopsies were obtained and revealed the
presence of aggregates of LAM cells with the same
phenotypic pattern detected at retroperitoneal biop-
sy, i.e. HMB-45-negative LAM cells. ERs-β were ex-
pressed at low levels in the lung specimens only.
Based on these findings a diagnosis of pulmonary
and extrapulmonary LAM was established. In
December 2006 treatment with triptoreline, a syn-
thetic analogue of Gn-RH (at the dose of 3.75 mg
every 4 weeks), was started; subsequent blood hor-
mone dosages confirmed the induction of iatro-
genic menopause. Seven months later, a CT scan re-
vealed that the size of the retroperitoneal lymph -
angioleiomyoma was reduced by approximately
80% (Figure 1, panel B); the caliber of the thoracic
duct was also reduced, while lung cysts were un-
changed. During this period the patient presented a
mild, self-limiting chyluria on two occasions.
Therefore, she underwent a retrograde bilateral
ureteropyelography revealing a normal left urinary
tract and absence of hydronephrosis, whereas, on
the right side, extensive and dilated fistulous con-
nections between the urinary tract and retroperi-
toneal lymphatics were present (Figure 3); the ureter
stent was removed. In December 2007 the patient
was clinically re-evaluated and was still asympto-
matic; at that time, 18 months after initial presenta-
tion, lung function was basically unchanged (FEV1
3.1 L, FVC 3.9 L, TLC 5.28 L, RV 1.32 L). Chyluria
was absent and triptoreline treatment was contin-
ued. 
DISCUSSION
Estrogens have been implicated in the pathogenesis
of LAM based on a number of convincing signs of
evidence, including the identification of estrogen
receptors (ERs) in the context of LAM cells [9-11],
and the occurrence of the disease primarily in
women of childbearing age. However, hormonal
modulation (using a number of different approach-
es) has failed to provide consistent, reproducible
proof of efficacy [4,8,12,13]. In this regard, a recent
report suggested limited efficacy of triptoreline ther-
apy [14]. However, in this study on 11 patients (9 of
which had pathologic confirmation of their disease)
no data were reported concerning the expression of
estrogen receptors and HMB-45, and it is unknown
whether these 9 patients represented cases of LAM
in which LAMD-SM cells played a role. Importantly,
ER expression has been documented in HMB-45-
positive, but not in HMB-45-negative LAM cells [9],
although these data have not been confirmed. 
LAM is rare so there have been no controlled trials
of its management. Effective treatment for patients
FIGURE 2: HIGH RESOLUTION COMPUTED TOMOGRAPHY
OF THE LUNG SHOWING 5 TO 7 mm BILATERAL CYSTS 
FIGURE 3: RETROGRADE BILATERAL URETEROPYELOGRAPHY 
A
B
Right upper urinary tract showing extensive fistulous
connections between urinary system and retroperitoneal
lymphatics (panel a) and normally shaped left urinary tract
(panel b).






























7 with LAM is still lacking and European Respiratory
Society (ERS) guidelines for LAM do not have con-
clusive indications about effective therapeutic
strategies [15]. 
Another recent report [7] shows that treatment with
sirolimus for 1 year has beneficial effects in pa-
tients with LAM, including the stabilization of FEV1
and improvement in FVC, quality of life, and some
functional performance measures. But sirolimus
therapy positively affected lung function only dur-
ing the treatment period and it was associated with
a large number of different adverse events. 
Here we report the identification of LAM cells neg-
ative for HMB-45 and expressing very low levels of
ERs in a young woman with a retroperitoneal mass
and lung cysts. The LAM cells found in our patient
closely resemble the spindle-shaped (LAMD-SM)
cells. Both in the lung specimens and in the
retroperitoneal mass ER levels were almost unde-
tectable. Similarly, Glassberg and colleagues report-
ed that the amounts of ER-α and ER-β protein were
lower in LAM tissue and LAMD-SM cell lines com-
pared to control lung tissue and cell lines [11]. In
this regard, it has been demonstrated that unbound
ERs undergo a rapid proteosome degradation in
LAMD-SM cells [16,17]. However, despite very low
ER protein levels, LAMD-SM are more responsive to
estrogens compared to control cells. This is not sur-
prising, because estrogen sensitivity and respon-
siveness only partially depend on the levels of func-
tional ERs [18]. In turn, the estrogen-ER interaction
drives matrix metalloproteinase (MMP)-2 and -9
synthesis and activation in LAMD-SM, thus leading
to tissue invasion and destruction [11]. HMB-45-
negative spindle cells have been shown to possess
a high proliferating-cell nuclear antigen expression
and have been implicated in the progression of
LAM [19]. The HMB-45-negative LAM cell occur-
rence is rare and we hypothesize that HMB-45-
negative LAM may represent a distinct disease phe-
notype, more aggressive but highly responsive to
hormonal therapy. In the case reported here, the
pharmacologic suppression of estrogen levels rapid-
ly reduced the size of a large retroperitoneal mass,
with consequent relief of urinary symptoms, and
stabilized the extension of the pulmonary cysts. We
therefore consider this case as indirect in vivo evi-
dence in support of the so-called “estrogen hypoth-
esis” in LAM. The fact that pregnancy and use of
oral contraceptives are associated with a higher fre-
quency of exacerbations and a more aggressive dis-
ease course, along with reports of LAM in post-
menopausal women taking hormone replacement,
reinforce this theory [20-22]. The patient described
here displayed other peculiar features meriting fur-
ther discussion. Chyluria was the presenting symp-
tom and we hypothesize that the presence of a fis-
tulous connection between the urinary system and
the retroperitoneal lymphatic system might have
been responsible for this unusual presentation of
LAM. Interestingly, chyluria completely disap-
peared after hormonal treatment, due to the dramat-
ic reduction in size of the retroperitoneal mass. In
this patient the early occurrence of such an atypical
urinary presentation prompted adequate treatment
that might have been able to stop disease progres-
sion at a time when pulmonary function was only
mildly impaired, but after confirmation of LAM cells
in the lung tissue. Taken together, these findings un-
derscore the importance of a high diagnostic suspi-
cion of LAM in young women presenting with atyp-
ical clinical manifestations.
The role of estrogens in the pathogenesis of LAM re-
mains poorly understood, and hormonal therapy
(based on the antagonism of estrogen effects) is em-
piric and unproven. Nevertheless, our in vivo find-
ings, coupled with recent evidence of limited effica-
cy of other therapeutic options, strongly suggest that
hormonal therapy may still hold promise at least in
some LAM patients.
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